// App-Quantinova.ai

P296 : Effect of upadacitinib on patient-reported symptoms by the new Ulcerative Colitis Symptoms Questionnaire (UC-SQ) in patients with moderate to severe ulcerative colitis: data from the Phase 2b study U-ACHIEVE

Researchers

Presenter

  • S Ghosh

Principal Investigators

  • F Aberra

  • R Cross

  • W Zhou

  • N Chen

  • W-J Lee

  • R Panaccione

Medical Centers

  • University of Birmingham, Institute of Immunology and Immunotherapy, NIHR Biomedical Research Centre, Institute of Translational Medicine, Birmingham, UK

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • University of Maryland School of Medicine, Baltimore, MD

  • AbbVie, Inc., North Chicago, IL

Locations

  • United Kingdom

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • II

Study Id's

  • NCT02819635

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved